Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quick Listen: Scrip’s Five Must-Know Things

Weekly Audio Catch-Up

Executive Summary

Join us for an audio roundup of major events in the international biopharma industry over the past week, as reported by Scrip's global team.

Take a brief audio tour around Scrip's Five Must-Know Things, this time covering major developments in the business week ended 2 October 2020.

In this edition, the industry pushes back on claims it could move even faster on coronavirus vaccines, promising results are reported for a COVID-19 antibody cocktail, US House hearings on pricing get off to a slow start, top-level executive changes are announced, and a progress update on a major acquisition.

This and other Informa Pharma Intelligence podcasts are also now voice-accessible as a skill on Alexa smart speakers and the Alexa app, under the "Business and Finance" category. Just say “Alexa, Open Informa - Pharma Intelligence" and then ask for a specific podcast or topic.

Stories mentioned in this episode:

(Also see "Moderna CEO Bancel Pushes Back On Trump Debate Comments On COVID-19 Vaccine" - Scrip, 30 Sep, 2020.)

(Also see "Regeneron’s COVID-19 Antibody Cocktail Shows Early Promise, But Does It Merit An EUA?" - Scrip, 30 Sep, 2020.)

(Also see "US House Drug Pricing Hearings Start Slow As Pharma Execs Dodge Some Punches" - Scrip, 30 Sep, 2020.)

(Also see "Changing Of The Guard At Merck KGaA With Garijo Succeeding Oschmann As CEO" - Scrip, 29 Sep, 2020.)

(Also see "Nearly One Year Post-Celgene: BMS CMO On Pipeline Progress, Clinical Trial Diversity" - Scrip, 24 Sep, 2020.)


Related Content





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts